Kadmon Reports Positive Interim Results from Phase 2 Trial of KD02

Kadmon Reports Positive Interim Results from Phase 2 Trial of KD02

Kadmon Holdings shares were up over 10% pre-market Tuesday after the company unveiled positive interim results from its ongoing phase 2 clinical trial evaluating KD02, in patients with previously treated chronic graft-versus-host disease (“cGVHD”). In a preliminary analysis, KD025 demonstrated a favorable safety and tolerability profile in all patients and an overall response rate (“ORR”) of 71%. cGVHD is a serious complication following allogeneic bone marrow or stem cell transplantation. […]

Read More ˃